How we made the decision

We check our guidelines regularly to ensure they remain up to date. We based the decision on surveillance 4 years after the publication of NICE's guideline on intravenous fluid therapy in adults in hospital (CG174) in 2013.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.


We found 89 studies in a search for systematic reviews and randomised controlled trials published between 12 March 2013 and 29 October 2016. We also considered 1 additional study identified by members of the guideline committee who originally worked on this guideline.

From all sources, we considered 90 studies to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: summary of evidence from surveillance for details of all evidence considered, and references.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline. See appendix B for stakeholders' comments and our responses.

Five stakeholders responded to the consultation not to update the guideline with 2 stakeholders providing comments.

Of the 2 stakeholders who commented on the proposal not to update the guideline: 1 agreed with the decision and 1 disagreed with the decision. The remaining 3 stakeholders did not have any comments to submit. One of the stakeholders suggested that there should be a dedicated lead in hospitals rather than this being additional to a clinician's existing role. However, NICE guideline CG174 already recommends that hospitals should have an intravenous (IV) fluids lead, responsible for training, clinical governance, audit and review of IV fluid prescribing and patient outcomes.

See ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett and Kay Nolan (from February 2017)
Associate Director

Philip Alderson
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

Yolanda Martinez
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2448-6

This page was last updated: